
Michael O Koch MD FACS
Surgical Oncology
Chairman and Professor of Urology Indiana University School of Medicine
Join to View Full Profile
535 Barnhill Dr# ROUTE420Indianapolis, IN 46202
Phone+1 317-944-7338
Fax+1 317-278-0499
Dr. Koch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Koch is a urology specialist located in Indianapolis, IN, with a subspecialty in surgical oncology. He completed his medical education at Geisel School of Medicine at Dartmouth and his residency in urology at Vanderbilt University Medical Center. He serves as Chairman and Professor of Urology at Indiana University School of Medicine since 1998, following a tenure as an Assistant/Associate Professor at Vanderbilt University School of Medicine. His expertise includes urologic oncology, minimally invasive urologic surgery, bladder cancer, kidney and ureteral stones, and robotic surgery. Dr. Koch has authored several publications and been involved in various clinical trials. His accolades include being named among America's Top Doctors by Castle Connolly from 2011 to 2015 and America's Top Doctors for Cancer from 2010 to 2015.
Education & Training
Vanderbilt University Medical CenterResidency, Urology, 1984 - 1987
Dartmouth-Hitchcock Medical Center1984
Geisel School of Medicine at DartmouthClass of 1981
Certifications & Licensure
IN State Medical License 1998 - 2027
TN State Medical License 1986 - 1999
American Board of Urology Urology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2015
- America's Top Doctors for Cancer Castle Connolly, 2010-2015
- Indianapolis Monthly Castle Connolly, 2007, 2009-2014
Clinical Trials
- Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence Start of enrollment: 1999 Jun 14
- High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer Start of enrollment: 2001 Oct 01
- Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate Start of enrollment: 2001 Oct 01
Publications & Presentations
PubMed
- Comparative analysis of machine learning-derived nomogram and biomarkers in predicting side-specific extraprostatic extension: Preliminary findings.Ruchika Reddy Chimmula, Mark Green, Mark Tann, Michael Koch, Ronald Boris
Clinical Imaging. 2025-09-01 - 2 citationsGender-affirming Robotic Tubularized Peritoneal Vaginoplasty: Feasibility and Outcomes.Ashley W Johnston, Mary E Soyster, Michael O Koch, Joshua D Roth
Urology. 2025-01-01 - 8 citationsComparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer ...Clinton D Bahler, Isamu Tachibana, Mark Tann, Katrina Collins, Jordan K Swensson
The Journal of Urology. 2024-08-01
Journal Articles
- A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence After Robot-Assisted Radical Prostatectomy with or Without a Small Intestinal Submucosa...Naveen Kella, Michelle A Boger, Michael O Koch, Steven M Lucas, Chandru P Sundaram, Clinton D Bahler, Thomas A Gardner, The Journal of Urology
Authored Content
- Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018
Press Mentions
IU Clinical Trial Aims to Improve Quality of Life for Prostate Cancer SurvivorsSeptember 30th, 2025
Illuccix Approved by FDA as Prostate Cancer Imaging AgentApril 15th, 2022
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging AgentApril 14th, 2022
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









